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Predictors of age of diagnosis and survival of Alzheimer’s disease in Down 
syndrome  
 
Abstract 
Background: People with Down syndrome (DS) are an ultra-high risk population for 
Alzheimer’s disease (AD). Understanding the factors associated with age of onset and 
survival in this population could highlight factors associated with modulation of the amyloid 
cascade.  
Objective: This study aimed to establish the typical age at diagnosis and survival associated 
with AD in DS and the risk factors associated with these.   
Methods: Data was obtained from the Aging with Down Syndrome and Intellectual 
Disabilities (ADSID) research database, consisting of data extracted from clinical records of 
patients seen by community  Intellectual Disability services (CIDS) in England. Survival 
times when considering different risk factors were calculated. 
Results: The mean age of diagnosis was 55.80 years, SD 6.29. Median survival time after 
diagnosis was 3.78 years, and median age at death was approximately 60 years. Survival 
time was associated with age of diagnosis, severity of intellectual disability, living status, 
anti-dementia medication status and history of epilepsy. Age at diagnosis and treatment 
status remained predictive of survival time following adjustment.  
Conclusion: This study provides the best estimate of survival in dementia within the DS 
population to date, and is in keeping with previous estimates from smaller studies in the DS 
population. This study provides important estimates and insights into possible predictors of 
survival and age of diagnosis of AD in adults with DS, which will inform selection of 
participants for treatment trials in the future. 
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Introduction 
Down syndrome (DS) is primarily due to trisomy of chromosome 21, which includes the 
amyloid precursor protein (APP) gene. Triplication of this gene is associated with 
overproduction of amyloid-beta with amyloid deposits in the brains of virtually all adults with 
DS and trisomy 21 is therefore a genetic form of Alzheimer's disease (AD) alongside 
mutations in APP which is associated with familial AD [1]. Life expectancy for people with 
Down syndrome (DS) has improved dramatically over past decades, from just 12 years in 
1942 to 60 years in 2003 [2], revealing early onset dementia as a major clinical concern in 
this population. However, reported prevalence of clinical dementia varies despite the neuro-
pathological hallmarks of Alzheimer’s disease being present in the brains of all adults with 
DS by age 35 [3]. Dementia prevalence has been estimated to increase from  9% between 
the ages of 45-49 years; 18% between ages 50-54 years; and 32% between ages 55-59 
years, reflecting a doubling of prevalence every 5 years [4], while longitudinal studies 
estimated cumulative risk to be 90% by age 65 [5]. However, these studies have included 
relatively small numbers of individuals with DS and dementia, and further information on the 
characteristics and prognosis of individuals with DS and dementia is required.  
Clinical factors that predict age of onset of sporadic AD in the general population include 
female sex [6], lifestyle factors as indicated by cardiovascular risk factors [7] and midlife 
adiposity [8] physical and mental health co-morbidities and psychosocial factors including 
lower educational and occupational level as well as age at retirement [9,10]. After diagnosis, 
women may have a faster rate of cognitive and functional decline [6, 7] and higher 
educational attainment have been shown to be associated with more rapid decline [7, 11]. 
Age at diagnosis may also affect rate of decline [11]. With regards to genetic factors, APOE 
genotype is known to affect age at onset [12] and in individuals with familial AD, the 
mutation-type appears to have a strong effect on age of onset [13].   
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Factors associated with the large variation in age of clinical presentation of AD and 
subsequent rate of decline in DS remain unclear. Given that this is an ultra-high risk 
population with AD without significant cardiovascular risk factors, it is important to 
understand the factors associated with both age of onset and survival in this population as it 
could highlight factors associated with modulation of the amyloid cascade.  
This study aimed to address these shortcomings by investigating the natural history of 
dementia in a cohort of individuals with DS who have been diagnosed with dementia in 
England, UK. This dataset allows longitudinal analysis of the course of dementia in a large 
clinically representative sample of adults with DS including participants from both 
institutional and community living backgrounds, and individuals across the range of severity 
of intellectual disability (ID). We aimed to establish the typical age at diagnosis and survival 
associated with AD in DS and the risk factors associated with these. We were particularly 
interested in whether age at diagnosis and survival were influenced to the same extent as in 
sporadic Alzheimer's disease (SAD) by sex/gender and co-morbid health conditions.  
Materials and Methods 
Sample 
The Aging with Down Syndrome and Intellectual Disabilities (ADSID) research database 
consists of data extracted from clinical records of patients referred to community Intellectual 
Disability services (CIDS) for memory screening or dementia assessments for adults with ID 
in England. Data was extracted from clinical records using pseudonymised and standardized 
record forms, allowing for longitudinal tracking of participants’ assessments from first 
screening. Data extraction varied according to site, in some cases clinicians anonymized 
and recorded data, in other cases, researchers visited the site and anonymized and 
recorded data on site. Participating areas included services with sufficiently detailed 
assessments available from London and Southern England. All adults with DS who had 
received baseline screening or an assessment for dementia by CIDS were eligible for 
Age of diagnosis and survival of AD in DS 
6 
inclusion in the database, providing a clinically representative sample of adults with DS 
across the range of ID and residing in a variety of settings. For the present analysis, we 
selected all cases with both DS and a confirmed diagnosis of dementia at their most recent 
assessment. Cases where DS and/or current dementia status was recorded as uncertain, 
and when date of diagnosis was not recorded, were excluded. 
Ethical review and approvals: 
Approval was given by the central NHS Research Ethics Service as well as the National 
Information Governance Board (NIGB) which allowed us to collect pseudonymized 
retrospective data without requiring individual consent. This was necessary in order to use 
data relating to patients who had died.  
Variables of interest: 
Variables extracted for this analysis were age and date at diagnosis, date of death or date of 
last assessment if patient was alive, sex, severity of ID, health co-morbidities (epilepsy, 
history of depression and/or anxiety, thyroid disorder, and sensory impairment), living 
situation, region, and anti-dementia medication status. 
Definition of dementia 
Dementia was diagnosed after comprehensive assessment by clinicians based in 
participating CIDS's, with experience in assessing DS individuals for dementia. Diagnostic 
assessments typically included a detailed history of cognitive symptoms (in most areas 
supplemented by validated tools such as the Dementia questionnaire for People with ID [14] 
medical history, routine health check followed by investigations as required to exclude 
untreated physical health problems, psychiatric evaluation to exclude mental illness if 
indicated, and neuropsychological testing although specific tests varied between services.   
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In instances when a possible dementia diagnosis was recorded but then removed before 
being re-diagnosed at a later date, date of diagnosis was recorded as the date from which a 
consistent dementia diagnosis was given at all subsequent assessments. 
Other definitions 
Severity of Intellectual Disability was defined according to descriptions in the ICD-10 
classification; we used three categories (mild, moderate, severe to profound). Categorization 
was determined by IQ if a standardized score at first assessment was available or by British 
Picture Vocabulary Scale (BPVS) [15] at first assessment if IQ was not available. BPVS raw 
scores were converted to age equivalents. BPVS age >6 years old was classified as mild ID, 
age 3-6 years as moderate ID, and age <3 years as severe to profound. If neither IQ nor 
BPVS scores were available, severity was as recorded in clinical notes.  
Health co-morbidities: Epilepsy was defined according to presence or not of pre-existing 
clinically diagnosed epilepsy recorded at first assessment to capture those with epilepsy 
morbidity prior to dementia-related seizure onset.  
History of depression and/or anxiety was based on any medical history of clinically 
diagnosed depression and/or anxiety at first assessment.  
Thyroid disorder was defined as a recorded diagnosis of thyroid disorder at any assessment. 
If specific thyroid disorder information was not provided but medication history was available, 
common thyroid medications (Thyroxine, Levothyroxine, and Carbimazole) were taken as 
confirmation of thyroid disorder.  
Sensory impairment was defined according to visual and/or hearing impairment being 
recorded in the clinical notes at first assessment.  
Living status denotes whether a patient was living with family or away from family at first 
assessment. While living status does change and dementia in the DS population is 
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associated with relocation as care needs change, this variable should capture living situation 
prior to and during the time of dementia onset. 
Anti-dementia drug treatment: treatment status has been defined according to whether the 
patient had taken any relevant drugs (Donepezil, Galantamine, Rivastigamine, and 
Memantine) at any recorded time point, creating a binary (yes/no) composite covariate. 
Age of onset was defined as time in years between date of diagnosis and date of birth. 
Survival time was defined as the time from the initial date of diagnosis of dementia until the 
date of death or last follow-up.  
Analysis 
All participants alive at time of data collection were censored at the date of their last 
assessment. If participants had no further assessments after diagnosis, and no date of death 
was known, duration of disease could not be calculated and these participants were 
necessarily excluded from analyses of survival. 
T-tests or Anova were used to assess the relationship between age at diagnosis and 
patients’ clinical and demographic characteristics. We used the Kaplan-Meier method to 
estimate the median survival [16]. Univariable Cox regression models were fitted for each 
predictor. The proportional hazards assumption required by the Cox model [17] was 
investigated using Schoenfeld residuals [18]. In addition, for numerical predictors the 
assumption of linear relationship was also checked. 
Multivariable analyses were used to estimate the combined effect of the predictors on both 
age at diagnosis and survival models. We used the enter procedure to adjust for 
confounding, using a 20% significance level.   
Data analyses were carried out in SPSS v 22. 
Results 
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The sites included in this analysis included data from 839 individuals with Down syndrome of 
whom 254 (30.3%) had dementia and 251 (55.4% male) participants were eligible for this 
study with a recorded date of diagnosis. Follow-up data post-diagnosis required for survival 
analysis was available for 194 (77.3%) participants. Comparisons between those with and 
without follow-up data revealed no differences in demographics (sex, living situation or age 
at diagnosis) but there were significant regional differences in follow-up rates. Region was 
therefore used as fixed effect in subsequent survival analyses. Table 1 displays the 
characteristics of eligible participants and missing data for each variable. 
Age of dementia diagnosis and predictors 
The mean age of diagnosis was 55.80 years, SD 6.29. There was large variation in age at 
diagnosis, ranging from 35.46 years to 74.46 years, but it was normally distributed, with an 
interquartile range between 51.67 years and 59.79 years; i.e. approximately 50% of 
individuals with Down syndrome and dementia were diagnosed in their 6th decade (figure 1).  
Table 2 displays differences in age at diagnosis by clinical and demographic variables. Men 
tended to be diagnosed slightly later than women - (56.59 years, SD 6.65 vs. 54.84 years, 
SD 5.68; p = 0.029), and other variables associated with age at diagnosis included living 
situation and sensory impairment. We therefore conducted a multivariate regression analysis 
(n = 187) using the variables associated with significant differences in age at diagnosis to 
adjust for confounding. The corresponding estimates and 95% Confidence Intervals (CI) for 
gender, sensory impairment and living situation were: -0.64 (-2.37 to 1.08; p = 0.463); -1.86 
(-3.75 to 0.03, p =0.054), and 3.24 (1.01 to 5.46, p=0.005) respectively (R2 = .078, F = 
5.182, p = .002). Living situation remained the only significant predictor of age at diagnosis, 
though presence of sensory impairment showed a trend towards statistical significance.  
Survival time 
There were 108 (43.0%) recorded deaths during follow-up, with a mean age at death of 
59.98 years, SD 5.98, range 46.9 – 75.0 years.  For men the mean age at death was 59.99 
Age of diagnosis and survival of AD in DS 
10 
years (SD 6.88); and for women 59.96 years (SD 4.68). Kaplan-Meier survival time 
estimates from time of diagnosis revealed a median survival time of 3.78 years (95% CI 3.11 
- 4.45).   
Predictors of survival  
Survival analysis using Kaplan-Meier estimates revealed significant differences between 
men and women, with shorter survival in men compared to women (median survival in men 
3.10 years, 95% CI 2.60 – 3.63;  women 4.40 years, 95% CI 3.69 – 5.11; p=0.004). Kaplan-
Meier survival analysis also revealed that age at diagnosis (n=194) was the strongest 
predictor of survival (p < 0.001), such that those diagnosed before age 50 had a median 
survival of 4.94 years (95% CI 2.22 -  7.66), compared to those diagnosed between 50-60 
who had a median survival of 4.06 years (95% CI 3.36 – 4.75) and those diagnosed after 60 
with a median survival of 2.56 years (95% CI 1.56 – 3.58) (figure 2C). Level of ID (n=111) 
was also a significant predictor of survival (p = 0.002); median survival was 9.08 years (95% 
CI not estimated) for Mild ID; 6.15 years (95% CI 3.53 – 8.78) for moderate ID, and 2.60 
years (95% CI 0.44 – 4.75) for those with severe ID. The difference between these groups 
were most noticeable during the first 5 years following diagnosis (figure 2D).  
Those living with their families also had a survival advantage compared to those that were 
living in residential settings or independently (median survival 5.59 years, 95% CI 1.13 – 
10.05 years vs. 3.45, 95% CI 2.80 – 4.09; p = 0.03) but this difference became less 
prominent the longer the time lapse after diagnosis (figure 2A).  
Those with pre-morbid epilepsy (i.e. before the onset of dementia) also had marginally 
reduced median survival (3.10 years, 95% CI 2.69 – 3.50), compared to those without 
epilepsy (3.78 years, 95% CI 3.06 – 4.50; p = 0.054). The difference in survival associated 
with epilepsy was more prominent in the later stages of AD (figure 2E). History of depression 
(p = 0.167), sensory impairment (p = 0.330) and thyroid dysfunction (p = 0.407) were not 
associated with survival. 
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Those prescribed anti-dementia drugs had a survival advantage compared to those not 
prescribed these medications (median survival 6.14 years, 95% CI 5.23  – 7.05 vs. 3.25 
years, 95% CI 2.83 – 3.66; p = 0.003) (figure 2F).  
Hazard ratios for these factors adjusted for region are given in table 3.  
Multivariate Cox proportional hazards regression was then run including only those variables 
significantly associated with survival at the 20% level while adjusting for region (n = 92). Age 
at diagnosis (HR 1.07, 95% CI 1.01 – 1.14; p = 0.021) and moderate ID compared to severe 
ID (HR 0.42, 95% CI 0.18 – 0.98; p = 0.045) remained the only significant predictors of 
survival.  
A sensitivity analysis was also conducted excluding severity of ID because it had more than 
30% missing values. Age at diagnosis (HR 1.04, 95% CI 1.01 to 1.08, p=0.026) and 
prescription of anti-dementia medication were shown to be significant predictors of survival 
(HR 0.43, 95% CI 0.21 – 0.89; p = 0.023) (n=160).   
Discussion 
In this large representative clinical cohort of adults with DS and AD the mean age of 
diagnosis with dementia was 55.8 years of age, and approximately  50% of dementia cases 
were diagnosed in their 6th decade, with a quarter presenting before age 51, and a further 
quarter presenting at age 60 or older. Age at diagnosis was associated with gender (men 
being diagnosed slightly later), living situation, and sensory impairment. Having sensory 
impairment delayed diagnosis by more than 2 years, and living with family was associated 
with younger age at diagnosis. Individuals living with family typically were diagnosed more 
than 4.5 years earlier than those living away from family. However, only living situation 
remained predictive after adjustment for potential confounders. 
Median survival time after diagnosis was 3.78 years, and median age at death was 
approximately 60 years. Survival time was associated with age of diagnosis, severity of ID, 
living status, anti-dementia medication status, and history of epilepsy, but none of the other 
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health co-morbidities were predictive of survival. Age at diagnosis and treatment status 
remained predictive of survival time following adjustment. Similar to findings from the 
general population, older age of diagnosis was predictive of shorter survival. An increase in 
age at diagnosis of one year is associated with an increased mortality risk of approximately 
7%.  
Strengths and limitations 
As a consequence of the use of clinical data for the analysis, missing data for some 
variables was unavoidable. Multivariate analyses were therefore based on a smaller number 
of cases; however, this remains the largest study of dementia in DS to date. Furthermore, 
our sampling method ensured a representative sample of individuals with DS with dementia, 
and captured cases across large regions of Southern England, who had a range of ID 
severity and comorbidities.  
We used age at diagnosis as proxy of age of onset, but this may have underestimated age 
of onset. Our methodology is however comparable to similar studies of AD in the general 
population, and therefore allows for comparison with these studies. Furthermore, knowledge 
of typical survival from point of diagnosis is probably more useful for prognostic decisions. 
Nevertheless, estimates or age of onset and survival may change when there is more 
emphasis on early diagnosis, particularly if effective treatments become available.  
As data were collected from clinical records, and participants were born several decades 
ago, genetic testing to confirm Down syndrome diagnosis was not consistently available. As 
with any clinical research, it is possible that other unmeasured variables are confounding the 
relationships found here. Additionally our health-related measures and medication variables 
were broadly defined, and clinical assessments were variable between sites, leading to 
some heterogeneity which may have masked more specific effects. For example, it was not 
always clear if hearing or visual impairments were corrected. We do not have data regarding 
reliability across data collection, which may also have contributed to heterogeneity. 
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Age of dementia diagnosis:  
This is the largest cohort of people with DS and dementia to our knowledge, which allows us 
to provide accurate estimates of the typical age of dementia diagnosis. Our findings 
demonstrate the young age of dementia diagnosis in the DS population, as well as the 
considerable variation in age at diagnosis ranging between 35 and 74 years. Typical 
diagnosis was in the 6th decade, compared to a typical diagnosis age in the 8th – 9th decade 
for sporadic Alzheimer's disease. Variation in age at diagnosis may be partially explained by 
diagnostic issues, such as the difficulty making a diagnosis in the presence of sensory 
impairments [19]. It is possible that clinicians have misdiagnosed some individuals, though 
clinical dementia diagnosis in this population has been found to have good inter-rater 
reliability [20]. Nevertheless, the failure to predict much of the variation in age at diagnosis 
with most of the variables measured, suggests that unmeasured factors including genetic 
variability such as APOE status also play an important role in individuals with DS. APOE 
genotype has been shown to influence age of dementia onset in the general population, and 
in the DS population, but genotyping is not currently used in clinical practice [21] and we 
therefore did not have data on APOE status of participants.  
In contrast to the general population we did not find a convincing gender difference in age at 
diagnosis of dementia in the DS population after adjusted analyses, in keeping with other 
studies [4,22]. However, one previous study found women to be at higher risk but with no 
difference in age of onset when APOE genotype was accounted for [23] and another found 
higher risk of dementia in men, along with earlier onset [24].  
The brain reserve theory predicts that age of onset of dementia should be earlier in adults 
with more severe intellectual disability [25] and has been demonstrated in studies of AD in 
the general population [26]. Baseline severity of ID was not however associated with age of 
dementia diagnosis in this study of older adults with DS. A few previous studies have 
demonstrated lower baseline cognitive function to be related to younger age at onset [27], 
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but others have found no association [28]. It is possible that the inherent difficulties in 
diagnosing dementia in those with more severe disability could mask differences in 
symptoms at onset, and the  amount of missing data for this variable is an additional 
limitation. 
We found a relationship with living situation, which remained significant after adjusting for 
other variables. The reasons why those living with their families were diagnosed several 
years before their peers living in other settings are unclear, but the most likely possibility is 
that family members who know the person with DS well may detect behavior change and 
other symptoms of dementia at an earlier stage than support staff in communal homes who 
are more likely to change frequently and therefore know the person less well. It is also 
possible that those living at home may differ from those living in other settings on other 
factors, but living situation was not a significant predictor of survival in our adjusted 
analyses, suggesting that the two groups did not differ on health co-morbidities that are 
usually associated with poor survival. 
Predictors of survival:  
In the general population, sporadic Alzheimer’s disease (SAD) has a high associated 
mortality risk, significantly shortening life expectancy, with survival time from disease onset 
in the general population ranging from 3.3 to 11.7 years across studies [5]. Mortality risk 
associated with SAD was consistently predicted by age of onset and commonly also by male 
sex. Furthermore, survival varied from 10.7 years for onset age between 65-69 years to 4.3 
years for onset age between 80-89 years. However, studies with broader inclusion criteria 
i.e. including those with various types of dementia estimated survival to be shorter, while 
those focused on Alzheimer’s type dementia may have longer survival estimates [29]. For 
example, a recent estimate of survival based on over 400 incident broadly defined dementia 
cases in a general population cohort found a median survival time post-diagnosis of 4.6 
years in women and 4.1 years in men [30].  
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Survival rates in this study of adults with DS and AD were much shorter if compared against 
rates from the equivalent age group in the general population; e.g. survival in our study for 
adults with DS aged 60 and older was between 2 and 3 years, compared to more than 10 
years for those of similar age in the general population [30]. Due to the earlier age of 
dementia onset in the DS population, average age at death was approximately 60 years 
compared to 90 for women and 87 years for men with dementia in the general population 
[30]. As in the general population, shorter survival time was strongly predicted by older age 
of diagnosis.  
Other research has also suggested that various health co-morbidities, particularly vascular 
risks, neuropsychiatric complications [31] as well as dementia severity [32] may be 
associated with shorter survival time.  
This study provides the best estimate of survival in dementia within the DS population to 
date, and is in keeping with previous estimates from smaller studies in the DS population 
[33,34].  
Unlike some previous studies which have demonstrated a lack of gender difference in typical 
life expectancy in the DS population[4], we have shown that in those diagnosed with 
dementia, men tended to have shorter survival than women in unadjusted though not in 
adjusted analyses. This may be due to women being  diagnosed at a slightly earlier age, 
suggesting that perhaps signs of AD are more likely to be missed in men, resulting in later 
age of diagnosis and an apparently shorter survival time. 
A few smaller previous studies have suggested associations between the course of AD and 
DS and baseline cognitive function [35] or epilepsy [36]; however these findings have not 
been consistent across studies. We found some association between survival and severity 
of intellectual disability, with those with more severe disability being associated with worse 
survival, and also for epilepsy, though this association was no longer apparent after 
adjustment, suggesting that epilepsy status before the onset of dementia is not a strong 
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predictor of survival. Alternatively, this finding may be explained by documentation of 
epilepsy at the first assessment reflecting prodromal rather than premorbid epilepsy, with 
dementia-related epilepsy being diagnosed prior to the dementia.  
It was unexpected that those individuals taking any of the current licensed medications for 
Alzheimer’s disease would have a significantly longer survival time than those who were not 
[37], as previous small trials in DS did not show significantly positive effects on cognition. In 
individuals with SAD these medications temporarily delay and reduce symptoms, and may 
delay admission to higher care settings [38], but do not change the course of the disease, 
though some studies have shown an effect on survival [39]. It is not possible to conclude 
from the current findings whether improved survival was due to the medications themselves, 
selection bias, or due to related factors such as improved care and follow-up, or other 
interventions used in conjunction with medication. Nevertheless, our findings indicate that 
medication treatment (and associated monitoring and clinical input) is not associated with 
worse outcomes in DS than in SAD, and thus it is important to highlight equal access to anti-
dementia drug treatment in patients with DS and dementia, with a possibility that it may 
contribute to improved outcomes.  
Implications 
The excess of Alzheimer's type dementia in DS is presumed to be largely driven by genetic 
factors, particularly triplication of the APP gene, with AD in DS being a relatively pure form of 
AD without the general cardiovascular risk factors that is often comorbid with AD in the 
general population [40]. Our results suggest that there is some validity to this assumption, as 
we were not able to identify the usual factors associated with age of diagnosis and survival.    
Our findings showed that older age / delayed diagnosis of dementia is predictive of shorter 
survival, and that people living with families were diagnosed earlier than their peers. Some 
national changes to service delivery for people with ID (including replacing peer-group 
lifespan day services with individual care providers with more rapid staff turnovers) may act 
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as barriers to the detection of early-onset dementia symptoms in people not living with their 
families.      
Our study demonstrated some role for demographic and health comorbidities as predictors 
of age at diagnosis, which in combination with genetic factors such as APOE status could be 
used to identify those at most risk for future trials of preventative treatments. The finding that 
medication such as acetylcholinesterase inhibitors may have a positive impact upon survival 
in this population is intriguing and deserves further consideration. Important future directions 
for research could include studies exploring pre-clinical symptoms and mild cognitive 
impairment and their relationship between age at diagnosis and survival in this population. 
This study provides important estimates and insights into possible predictors of survival and 
age of diagnosis of AD in adults with DS, which will inform selection of participants for 
treatment trials in the future. In addition, it adds to the literature on clinical presentations 
associated with genetic forms of AD.  
Acknowledgments  
This project was funded by the North Central London Research Consortium (NoClor) and 
the Bailey Thomas Charitable Trust. We thank all the participating community intellectual 
disabilities services that have contributed data to this project. 
 
Conflict of Interest/Disclosure Statement 
Andre Strydom receives funding from the Wellcome Trust for the London Down Syndrome 
Consortuim (LonDownS). Andre Strydom and Amanda Sinai have acted as investigators for 
Roche Pharmaceuticals. 
 
References 
[1] Wiseman FK, Al-Jabani T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VLJ, Fisher 
EMC, Strydom A (2015) A genetic cause of Alzheimer disease: mechanistic insights 
from Down syndrome. Nat. Rev. Neurosci. 16, 564–574.  
Age of diagnosis and survival of AD in DS 
18 
[2] Bittles AH, Glasson EJ (2004) Clinical, social, and ethical implications of changing life 
expectancy in Down syndrome. Dev Med Child Neurol 46, 282–286.  
[3] Mann DM, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the 
brains of patients under 50 years of age with Down’s syndrome. J. Neurol. Sci. 89, 169–
179.  
[4] Coppus A, Evenhuis H, Verberne GJ, Visser F, van Gool P, Eikelenboom P, van Dujin C 
(2006) Dementia and mortality in persons with Down’s syndrome. Journal of Intellectual 
Disability Research 50, 768–777.  
[5] McCarron M, McCallion P, Reilly E, Mulryan N (2014) A prospective 14-year longitudinal 
follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res 58, 61–70.  
[6] Mielke MM, Vemuri P, Rocca WA. (2014) Clinical epidemiology of Alzheimer’s disease: 
assessing sex and gender differences. Clin Epidemiol 6, 37–48. 
[7] Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H (2015) Summary of the 
evidence on modifiable risk factors for cognitive decline and dementia: A population-
based perspective. Alzheimer’s & Dementia 11, 718–726. 
[8] Chuang YF, An Y, Bilgel M, Wong DF, Troncoso JC, O’Brien RJ, Breitner JC, Ferruci L, 
Resnick SM, Thambisetty M (2016) Midlife adiposity predicts earlier onset of Alzheimer’s 
dementia, neuropathology and presymptomatic cerebral amyloid accumulation. Mol 
Psychiatry 21, 910–915. 
[9] Lupton MK, Stahl D, Archer N, Foy C, Poppe M, Lovestone S, Hollingworth P, Williams 
J, Owen MJ, Dowzell K, Abraham R, Sims R, Brayne C, Rubinsztein D, Gill M, Lawlor B, 
Lynch A, Powell JF (2010) Education, occupation and retirement age effects on the age 
of onset of Alzheimer’s disease. Int. J. Geriat. Psychiatry 25, 30–36. 
[10] Grotz C, Letenneur L, Bonsang E, Amieva H, Meillon C, Quertemont E, Salmon E, 
Adam S (2015) Retirement Age and the Age of Onset of Alzheimer’s Disease: Results 
from the ICTUS Study. PLOS ONE 10, e0115056. 
[11] Peng D, Shi Z, Xu J, Shen L, Xiao S, Zhang N, Li Y, Jiao J, Wang Y-J, Liu S, Zhang M, 
Wang M, Liu S, Zhou Y, Zhang X, Gu X-h, Yang C-c, Wang Y, Jiao B, Tang B, Wang J, 
Age of diagnosis and survival of AD in DS 
19 
Yu T, Ji Y (2016) Demographic and clinical characteristics related to cognitive decline in 
Alzheimer disease in China. Medicine (Baltimore) 95. 
[12] Naj AC, Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, 
Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, 
Bird TD, Boeve BF, Baldwin CT, Jarvik GP, Crane PK, Rogaeva E, Barmada MM, 
Demirci FY, Cruchaga C, Kramer PL, Ertekin-Taner N, Hardy J, Graff-Radford NR, 
Green RC, Larson EB, St George-Hyslop PH, Buxbaum JD, Evans DA, Schneider JA, 
Lunetta KL, Kamboh MI, Saykin AJ, Reiman EM, De Jager PL, Bennett DA, Morris JC, 
Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, 
Martin ER, Haines JL, Mayeux RP, Farrer LA, Schellenberg GD, Pericak-Vance MA; 
Alzheimer Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold 
SE, Barber R, Barnes LL, Beach TG, Becker JT, Beekly D, Bigio EH, Bowen JD, Boxer 
A, Burke JR, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carrasquillo MM, 
Carroll SL, Chui HC, Clark DG, Corneveaux J, Cribbs DH, Crocco EA, DeCarli C, 
DeKosky ST, Dick M, Dickson DW, Duara R, Faber KM, Fallon KB, Farlow MR, Ferris S, 
Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, 
Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman 
BT, Jicha GA, Jin LW, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, 
LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lin CF, Lopez OL, 
Lyketsos CG, Mack WJ, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry 
SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Murrell JR, 
Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Peskind E, Petersen RC, Pierce A, 
Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Ringman JM, Roberson 
ED, Rosen HJ, Rosenberg RN, Sano M, Schneider LS, Seeley WW, Smith AG, Sonnen 
JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, 
Valladares O, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, 
Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, 
Younkin SG, Yu CE, Yu L (2014) Effects of Multiple Genetic Loci on Age at Onset in 
Age of diagnosis and survival of AD in DS 
20 
Late-Onset Alzheimer Disease: A Genome-Wide Association Study. JAMA Neurol 71, 
1394–1404. 
[13] Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, 
Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, 
Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, 
Xiong C, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer Network (2014) 
Symptom onset in autosomal dominant Alzheimer disease A systematic review and 
meta-analysis. Neurology 83, 253–260. 
[14] Evenhuis HM (1996) Further evaluation of the Dementia Questionnaire for Persons with 
Mental Retardation (DMR). Journal of Intellectual Disability Research 40, 369–373. 
[15] Dunn-Loyd M, Dunn LM, Whetton C, Burley J  The British Picture Vocabulary Scales. 
[16] Kaplan EL, Meier P (1958) Nonparametric Estimation from Incomplete Observations. 
Journal of the American Statistical Association 53, 457–481. 
[17] Cox DR (1972) Regression Models and Life-Tables. Journal of the Royal Statistical 
Society. Series B (Methodological) Vol. 34, 187–220. 
[18] Schoenfield D (1982) Partial residuals for the proportional hazards regression model. 
Biometrika 69, 239–241. 
[19] Strydom A, Chan T, Fenton C, Jamieson-Craig R, Livingston G, Hassiotis A (2013) 
Validity of criteria for dementia in older people with intellectual disability. Am J Geriatr 
Psychiatry 21, 279–288. 
[20] Sheehan R, Sinai A, Bass N, Blatchford P, Bohnen I, Bonell S, Courtenay K, Hassiotis 
A, Markar T, McCarthy J, Mukherji K, Naeem A, Pashos D, Perez-Achiga N, Sharma V, 
Thomas D, Walker Z, Strydom A  (2014) Dementia diagnostic criteria in Down 
syndrome. Int J Geriatr Psychiatry. doi:10.1002/gps.4228 
[21] Rohn TT, McCarty KL, Love JE, Head E (2014) Is Apolipoprotein E4 an Important Risk 
Factor for Dementia in Persons with Down Syndrome? J Parkinsons Dis Alzheimers Dis 
1. 
[22] Tyrrell J, Cosgrave M, McCarron M, McPherson J, Calvert J, Kelly A, McLaughlin M, 
Age of diagnosis and survival of AD in DS 
21 
Lawlor BA (2001) Dementia in people with Down’s syndrome. Int. J. Geriat. Psychiatry 
16, 1168–1174. 
[23] Lai F, Kammann E, Rebeck GW, Anderson A, Chen Y, Nixon RA (1999) APOE 
genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. 
Neurology 53, 331–331. 
[24] Schupf N, Kapell D, Nightingale B, Rodriguez A, Tycko B, Mayeux R (1998) Earlier 
onset of Alzheimer’s disease in men with Down syndrome. Neurology 50, 991–995. 
[25] Strydom A, Hassiotis A, King M, Livingston G (2009) The relationship of dementia 
prevalence in older adults with intellectual disability (ID) to age and severity of ID. 
Psychological Medicine 39, 13–21. 
[26] Valenzuela M J, Sachdev P (2006) Brain reserve and dementia: a systematic review. 
Psychological Medicine 36, 441–454. 
[27] Evenhuis HM (1990) The Natural History of Dementia in Down’s Syndrome. Arch Neurol 
47, 263–267. 
[28] Strydom A, Shooshtari S, Lee L, Raykar V, Torr JJ, Tsiouris J, Jokinen N, Courtenay K, 
Bass N, Sinnema M, Maaskant M (2010) Dementia in Older Adults With Intellectual 
Disabilities—Epidemiology, Presentation, and Diagnosis. Journal of Policy and Practice 
in Intellectual Disabilities 7, 96–110. 
[29] Garcia-Ptacek S, Farahmand B, Kareholt I, Religa D, Cuadrado ML, Eriksdotter M 
(2014) Mortality Risk after Dementia Diagnosis by Dementia Type and Underlying 
Factors: A Cohort of 15,209 Patients based on the Swedish Dementia Registry. Journal 
of Alzheimer’s Disease 41, 467–477. 
[30] Xie J, Brayne C, Matthews FE, and the Medical Research Council Cognitive Function 
and Ageing Study collaborators. (2008) Survival times in people with dementia: analysis 
from population based cohort study with 14 year follow-up. BMJ 336, 258–262. 
[31] Peters M E, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, Lyketsos CG 
(2015) Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimer’s 
Dementia and Death: The Cache County Dementia Progression Study. AJP 172, 460–
Age of diagnosis and survival of AD in DS 
22 
465. 
[32] Todd S, Barr S, Roberts M, Passmore AP (2013) Survival in dementia and predictors of 
mortality: a review. Int J Geriatr Psychiatry 28, 1109–1124. 
[33] Prasher VP, Krishnan VHR (1993) Age of onset and duration of dementia in people with 
Down syndrome: Integration of 98 reported cases in the literature. Int. J. Geriat. 
Psychiatry 8, 915–922. 
[34] Margallo-Lana ML, Moore PB, Kay DW, Perry RH, Reid BE, Berney TP, Tyrer SP (2007) 
Fifteen-year follow-up of 92 hospitalized adults with Down’s syndrome: incidence of 
cognitive decline, its relationship to age and neuropathology. Journal of Intellectual 
Disability Research 51, 463–477.  
[35] Temple V, Jozsvai E, Konstantareas MM, Hewitt T-A (2001) Alzheimer dementia in 
Down’s syndrome: the relevance of cognitive ability. Journal of Intellectual Disability 
Research 45, 47–55. 
[36] Lott IT, Doran E, Nguyen VQ, Tournay A, Movsesyan N, Gillen DL (2012) Down 
Syndrome and Dementia: Seizures and Cognitive Decline. J Alzheimers Dis 29, 177–
185. 
[37] Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu 
LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C, MEADOWS trial researchers 
(2012) Memantine for dementia in adults older than 40 years with Down’s syndrome 
(MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 379, 528–
536. 
[38] Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, 
Findlay D, Holmes C, Jones R, Rones R, McKeith I, macharouthu A, O’Brien J, Sheehan 
B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown RG, Banerjee S, Adams J, 
Johnson T, Bentham P, Phillips P (2015) Nursing home placement in the Donepezil and 
Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary 
and post-hoc analyses. The Lancet Neurology 14, 1171–1181. 
[39] Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M (2013) The use of 
Age of diagnosis and survival of AD in DS 
23 
cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide 
cohort study in subjects with Alzheimer’s disease. Eur Heart J 34, 2585–2591. 
[40] Buss L, Fisher E, Hardy J, Nizetic D, Groet J, Pulford L, Strydom A (2016) Intracerebral 
haemorrhage in Down syndrome: protected or predisposed? F1000Research 5, 876. 
Age of diagnosis and survival of AD in DS 
24 
Tables 
Table 1: Description of demographic and clinical characteristics 
 
All 
n (%) 
Total 251 
Age of onset  in years 
        Mean ( SD) 
 
 
55.81 (6.29) 
Sex   
 
Female 112 (44.6) 
Male 139 (55.4) 
Level of intellectual disability  
 
Mild 28 (11.2) 
Moderate 59 (23.5) 
Severe 48 (19.1) 
Missing 116 (46.2) 
Living 
 
With family 44 (17.5) 
Other 188 (74.9) 
Missing 19 (7.6) 
Epilepsy (Longstanding) 
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Present 46 (18.3) 
Absent 161 (64.1) 
Missing 44 (17.5) 
History of Depression 
 
Present  26 (10.4) 
Absent  146 (58.2) 
Missing 77 (30.7%) 
Thyroid Disorder 
 
Present 96 (38.2) 
Absent 92 (36.7) 
Missing 63 (25.1) 
Sensory Impairment 
 
Present 134 (53.4) 
Absent 58 (23.1) 
Missing 59 (23.5) 
Alzheimer's medication (acetylcholinesterase inhibitors or memantine) 
Prescribed 72 (28.7) 
       Not prescribed 162 (64.5) 
Missing 17 (6.8) 
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Table 2: Comparison of age at diagnosis by demographic and clinical characteristics 
 
 
Age at 
diagnosis 
Mean (SD) 
Difference 
95 % (confidence interval) 
p-value 
 Sex    0.029*     
 Female 54.84 (5.68)   
 Male 56.59 (6.65) 1.74 (-0.18 to 3.31)  
 
Level of intellectual disability  
  0.171 
Mild 55.05 (7.65)    
Moderate 54.30 (5.01)    
Severe 56.61 (6.89)    
 
Living situation 
  <0.001**   
 With family 51.93   
(6.04) 
-4.608 (-6.61 to -2.60  
 Other settings 56.54 
(6.08) 
reference  
 Epilepsy    0.649   
 No 55.37 
(6.51) 
reference  
 Yes 55.86 0.49 (-1.63 to 2.62)  
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(6.21) 
 Alzheimer's medication    0.099 
 
No 
56.21 
(6.65) 
reference  
 
Yes 
54.74 
(6.12) 
-1.49 (-3.23 to 0.28)  
 History of Depression    0.618   
 No 55.80 
(6.47) 
reference  
 Yes 55.11 
(6.66) 
-0.69 (-3.42 to 2.04)  
 Thyroid Disorder (n=188)   0.425 
 No 55.25 
(6.84) 
reference  
 Yes 55.96 
(5.11) 
-0.71 (-2.45 to 1.04)  
 Sensory Impairment (n=192)   0.015** 
 No 54.18 
(7.00) 
reference  
 Yes 56.74 
(5.49) 
2.56 (0.50 to 4.61)  
 Region   0.418 
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Region A 
55.10 
(6.70) 
  
 
Region B 
55.27 
(5.73) 
  
 
Region C 
56.23 
(6.22) 
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Table 3: Estimates of survival based on a Cox regression model – Univariate analyses  
 
HR+ 
95 % (confidence 
interval) 
p-value 
   
Age at diagnosis (n=192) 1.06 (1.03 to 1.09) < 0.001** 
Sex (n=194)  0.038* 
Female reference  
Male 
1.54 (1.02 to 2.31)  
Level of intellectual disability (n = 110) 
 0.058 
Mild reference  
Moderate  
1.13 (0.40 to 3.23)  
Severe 
2.41 (0.83 to 6.99)  
Living (n=184)  0.027**  
With family 
0.51 (0.28 to 0.93)  
Other reference  
Epilepsy (n=164)  0.057* 
No Reference  
Yes 
1.59 (0.99 to 2.56)  
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Alzheimer's medication (n=184)  0.015** 
No reference  
Yes 
0.45 (0.24 to 0.86)  
History of Depression (n=136)  0.092 
No reference  
Yes 
0.49 (0.22 to 1.12)  
Thyroid Disorder (n=150)  0.617 
No reference  
Yes 
1.12 (0.71 to 1.77)  
Sensory Impairment (n=147)  0.259 
No reference  
Yes 
1.38 (0.79 to 2.39)  
 
+Estimates obtained using Cox regression model adjusted for Site 
 
Age of diagnosis and survival of AD in DS 
31 
Figures 
Figure 1 – Distribution of age at Dementia diagnosis  
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Figure 2: Kaplan-Meier survival curves for A) accommodation setting – family home vs 
conglomerate setting, B) gender, C) age at diagnosis - young, middle, old, D) level of 
intellectual disability (Mild, moderate, severe), E) epilepsy, and F) treatment with dementia 
drugs (acetylcholinesterase inhibitors or memantine) 
 
 
 
 
 
 
 
A B 
C D 
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